Vonoprazan
Non-Erosive Gastroesophageal Reflux Disease (NERD)
Key Facts
About Phathom Pharmaceuticals
Phathom Pharmaceuticals is a focused, late-stage biotech dedicated to revolutionizing care for acid-related GI disorders through its novel PCAB technology. Founded in 2018, the company is progressing multiple Phase 2/3 clinical programs targeting significant unmet needs in Non-Erosive GERD and Eosinophilic Esophagitis. Its strategy centers on demonstrating superior efficacy and speed of onset compared to legacy proton pump inhibitors, with the goal of capturing substantial market share in a multi-billion dollar therapeutic landscape.
View full company profileAbout Phathom Pharmaceuticals
Phathom Pharmaceuticals is a focused, late-stage biotech dedicated to revolutionizing care for acid-related GI disorders through its novel PCAB technology. Founded in 2018, the company is progressing multiple Phase 2/3 clinical programs targeting significant unmet needs in Non-Erosive GERD and Eosinophilic Esophagitis. Its strategy centers on demonstrating superior efficacy and speed of onset compared to legacy proton pump inhibitors, with the goal of capturing substantial market share in a multi-billion dollar therapeutic landscape.
View full company profile